Literature DB >> 28953427

Comparison of Strategies of Treatment with Ranibizumab in Newly-Diagnosed Cases of Neovascular Age-Related Macular Degeneration.

Justus G Garweg1,2,3, Sophie A Niderprim1,2,3, Hanna Maria Russ3,4,5, Isabel B Pfister1,2,3.   

Abstract

PURPOSE: In several case-studies improved outcomes have been reported after switching from a pro-re-nata (PRN)- to a treat-and-extend (T&E)-based therapeutic approach in cases of neovascular age-related macular degeneration (nAMD). We therefore wished to compare the effects of instigating 2 different protocols in newly-diagnosed nAMD undergoing treatment with Ranibizumab.
METHODS: The outcomes of a PRN- and a T&E-based regime were retrospectively compared in treatment-naïve eyes under therapy with Ranibizumab for minimally 12 months in a routine clinical setting. The primary outcome measures included the proportion of the eyes with intraretinal fluid in OCT and visual stability after the initial drug-loading phase.
RESULTS: The comparative case-series included 107 eyes (PRN: 68; T&E: 39). During the 2-year follow-up period, a similar number of clinical examinations were performed in the 2 groups (PRN: 14.0 ± 6.2; T&E 13.4 ± 4.4; P = 0.97), whereas the number of injections that were administered differed for the first (PRN: 5.5 ± 2.0 vs. T&E 6.8 ± 2.4; P = 0.008) and the second year (PRN: 1.9 ± 2.0 vs. T&E 3.8 ± 2.3; P = 0.002). The proportion of eyes with intraretinal fluid after the initial drug-loading phase remained stable (PRN: from 33.8% to 36.4%; T&E: from 25.6% to 29.0%); so, too, did the central retinal thickness and the visual acuity.
CONCLUSION: Despite a limited sample size, this retrospective analysis revealed the anatomical and the functional improvements during the 2-year follow-up period to be not roughly different for the 2 strategies. However, when the PRN-approach is instigated, the risk of under-treatment due to lapses in visits or to over-extensions in the intervals between treatments may be underestimated.

Entities:  

Keywords:  PRN; Ranibizumab; intravitreal injections; pro-re-nata; treat-and-extend; wet age-related macular degeneration

Mesh:

Substances:

Year:  2017        PMID: 28953427     DOI: 10.1089/jop.2017.0006

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  5 in total

1.  Past and prognosis of anti-VEGF therapy for wet age-related macular degeneration-the future has begun.

Authors:  Justus G Garweg; J J Zirpel; C Gerhardt; Isabel B Pfister
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-05-09       Impact factor: 3.117

2.  Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration.

Authors:  Justus G Garweg
Journal:  Clin Ophthalmol       Date:  2019-07-19

3.  Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) - a meta-analysis.

Authors:  Justus G Garweg; Christin Gerhardt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-02-02       Impact factor: 3.117

4.  Treat-and-Extend Regimens for the Management of Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: Consensus and Recommendations From the Asia-Pacific Vitreo-retina Society.

Authors:  Voraporn Chaikitmongkol; Min Sagong; Timothy Y Y Lai; Gavin S W Tan; Nor Fariza Ngah; Masahito Ohji; Paul Mitchell; Chang-Hao Yang; Paisan Ruamviboonsuk; Ian Wong; Taiji Sakamoto; Anand Rajendran; Youxin Chen; Dennis S C Lam; Chi-Chun Lai; Tien Yin Wong; Chui Ming Gemmy Cheung; Andrew Chang; Adrian Koh
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2021-11-24

Review 5.  Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression.

Authors:  Daniele Veritti; Valentina Sarao; Valentina Soppelsa; Carla Danese; Jay Chhablani; Paolo Lanzetta
Journal:  J Clin Med       Date:  2022-01-10       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.